News2026-10-29 10:46 UTC

Eli Lilly blows past estimates, hikes sales outlook on Zepbound and Mounjaro demand

Eli Lilly reported earnings that exceeded analyst estimates and raised its sales outlook, citing strong demand for its weight‑loss drug Zepbound and diabetes medication Mounjaro. The company highlighted resilient market performance and updated guidance for upcoming quarters.

More News

10-29 10:48 UTCBitcoin holds near $80,000 ahead of earnings report
10-29 10:38 UTCAlphabet drags on Nasdaq futures as stock risks record post‑earnings loss Description: Shares fell over 10% in pre‑market trading, risking a 9.77% drop—the worst post‑earnings reaction ever—as AI chat and agents erode search revenue. Lower‑than‑expected capex guidance pressured cloud‑related stocks
10-29 10:58 UTCApple Announces Touchscreen MacBook Pro with OLED Display
10-29 10:58 UTCGoogle Unveils Gemini 4 Carbon with Limited Access
10-29 10:58 UTCThe Grid Enables Rapid PCB Production in the U.S.